Carmine Therapeutics, a Cambridge, MA-based EVX founded biotech company and emerging leader in non-viral gene therapies, held the first closing of its Series A financing.
All existing investors including EVX Ventures, and Simcere Pharmaceuticals participated, and they were joined by new lead Investor Huagai Capital, and others, including the Cystic Fibrosis Foundation. In conjunction with the financing, Deng Liang of Huagai Capital will be joining Elan Ezickson, Harvey Lodish, Ph.D., XQ Lin, and Don Haut, Ph.D. on Carmine’s Board of Directors.
The company plans to use the Series A funding to advance development of its first set of programs in retinal and pulmonary diseases toward the clinic.
Led by Don Haut, Ph.D. CEO, and XQ Lin, Chairman and Founder, Carmine is developing next-generation, non-viral gene therapies for a broad spectrum of diseases based on our proprietary Red Cell Extracellular Vesicle Gene Therapy (“REGENT™”) technology platform. The REGENT platform offers the potential to deliver therapeutic payloads to a broad array of tissues including the CNS, the ability to carry DNA or RNA payloads ranging from 20bp to >30kb as well as the ability to carry multiple payloads simultaneously.
The platform is based on the work of its scientific co-founders Minh Le, Ph.D., and Jiahai Shi, Ph.D. both of the National University of Singapore, and Harvey Lodish, Ph.D. of the Massachusetts Institute of Technology.
FinSMEs